{
  "trial_id": "NCT03674112",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, hormone receptor status, Eastern Cooperative Oncology Group (ECOG) performance status, left ventricular ejection fraction (LVEF), prior neoadjuvant chemotherapy completion, surgical treatment completion, wound healing status, planned adjuvant radiotherapy, planned adjuvant hormone therapy, intact skin at injection site, pregnancy status, history of active malignancy, history of serious cardiac illness, bone marrow function, renal function, liver function, presence of severe uncontrolled systemic disease, infection status, hypersensitivity to study drugs, chronic corticosteroid treatment.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline",
          "Eastern Cooperative Oncology Group (ECOG) performance status"
        ],
        [
          "Hormone Receptor Status",
          "hormone receptor status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Baseline Weight",
        "Number of Cycles of Prior Neoadjuvant Pertuzumab IV and Trastuzumab IV",
        "Prior Neoadjuvant Chemotherapy Regimen",
        "Pathological Complete Response (pCR) to Prior Neoadjuvant Treatment"
      ],
      "remaining_candidate_features": [
        "left ventricular ejection fraction (LVEF)",
        "prior neoadjuvant chemotherapy completion",
        "surgical treatment completion",
        "wound healing status",
        "planned adjuvant radiotherapy",
        "planned adjuvant hormone therapy",
        "intact skin at injection site",
        "pregnancy status",
        "history of active malignancy",
        "history of serious cardiac illness",
        "bone marrow function",
        "renal function",
        "liver function",
        "presence of severe uncontrolled systemic disease",
        "infection status",
        "hypersensitivity to study drugs",
        "chronic corticosteroid treatment"
      ]
    },
    "processed-gen-response": "Age, gender, hormone receptor status, Eastern Cooperative Oncology Group (ECOG) performance status, left ventricular ejection fraction (LVEF), prior neoadjuvant chemotherapy completion, surgical treatment completion, wound healing status, planned adjuvant radiotherapy, planned adjuvant hormone therapy, intact skin at injection site, pregnancy status, history of active malignancy, history of serious cardiac illness, bone marrow function, renal function, liver function, presence of severe uncontrolled systemic disease, infection status, hypersensitivity to study drugs, chronic corticosteroid treatment."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Hormone Receptor Status, ECOG Performance Status, Left Ventricular Ejection Fraction (LVEF), Time Since Surgery, Type of Neoadjuvant Chemotherapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Hormone Receptor Status",
          "Hormone Receptor Status"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline",
          "ECOG Performance Status"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Baseline Weight",
        "Number of Cycles of Prior Neoadjuvant Pertuzumab IV and Trastuzumab IV",
        "Prior Neoadjuvant Chemotherapy Regimen",
        "Pathological Complete Response (pCR) to Prior Neoadjuvant Treatment"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Left Ventricular Ejection Fraction (LVEF)",
        "Time Since Surgery",
        "Type of Neoadjuvant Chemotherapy"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Hormone Receptor Status, ECOG Performance Status, Left Ventricular Ejection Fraction (LVEF), Time Since Surgery, Type of Neoadjuvant Chemotherapy"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Eastern Cooperative Oncology Group (ECOG) performance status, Hormone receptor status, HER2 status, Left ventricular ejection fraction (LVEF), Prior chemotherapy, Prior radiotherapy, Prior hormone therapy, Surgical treatment type, Time from last systemic neoadjuvant therapy to randomization.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline",
          "Eastern Cooperative Oncology Group (ECOG) performance status"
        ],
        [
          "Hormone Receptor Status",
          "Hormone receptor status"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Baseline Weight",
        "Number of Cycles of Prior Neoadjuvant Pertuzumab IV and Trastuzumab IV",
        "Prior Neoadjuvant Chemotherapy Regimen",
        "Pathological Complete Response (pCR) to Prior Neoadjuvant Treatment"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Body Mass Index",
        "HER2 status",
        "Left ventricular ejection fraction (LVEF)",
        "Prior chemotherapy",
        "Prior radiotherapy",
        "Prior hormone therapy",
        "Surgical treatment type",
        "Time from last systemic neoadjuvant therapy to randomization."
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, Eastern Cooperative Oncology Group (ECOG) performance status, Hormone receptor status, HER2 status, Left ventricular ejection fraction (LVEF), Prior chemotherapy, Prior radiotherapy, Prior hormone therapy, Surgical treatment type, Time from last systemic neoadjuvant therapy to randomization."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), ECOG performance status, hormone receptor status, HER2 status, type of breast cancer (inflammatory, locally advanced, or early-stage), prior neoadjuvant chemotherapy, prior surgery, planned or ongoing adjuvant radiotherapy, adjuvant hormone therapy, left ventricular ejection fraction (LVEF), intact skin at planned site of subcutaneous injections.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline",
          "ECOG performance status"
        ],
        [
          "Hormone Receptor Status",
          "hormone receptor status"
        ],
        [
          "Prior Neoadjuvant Chemotherapy Regimen",
          "prior neoadjuvant chemotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Baseline Weight",
        "Number of Cycles of Prior Neoadjuvant Pertuzumab IV and Trastuzumab IV",
        "Pathological Complete Response (pCR) to Prior Neoadjuvant Treatment"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "HER2 status",
        "type of breast cancer (inflammatory, locally advanced, or early-stage)",
        "prior surgery",
        "planned or ongoing adjuvant radiotherapy",
        "adjuvant hormone therapy",
        "left ventricular ejection fraction (LVEF)",
        "intact skin at planned site of subcutaneous injections."
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), ECOG performance status, hormone receptor status, HER2 status, type of breast cancer (inflammatory, locally advanced, or early-stage), prior neoadjuvant chemotherapy, prior surgery, planned or ongoing adjuvant radiotherapy, adjuvant hormone therapy, left ventricular ejection fraction (LVEF), intact skin at planned site of subcutaneous injections."
  }
}